{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Phoenix&page=74&state=Arizona", "query": { "state": "Arizona", "city": "Phoenix", "page": 74 }, "page_size": 10 }, "pagination": { "page": 74, "page_size": 10, "total_count": 8152, "total_pages": 816, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Phoenix&page=75&state=Arizona&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Phoenix&page=73&state=Arizona&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T19:31:10.828Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03767348", "title": "Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)", "Microsatellite Instability-High (MSI-H)", "Non-melanoma Skin Cancer (NMSC)", "Cutaneous Melanoma" ], "interventions": [ { "name": "RP1", "type": "BIOLOGICAL" }, { "name": "nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Replimune, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 340, "start_date": "2017-09-20", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-27T19:31:10.828Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03767348" }, { "nct_id": "NCT03959085", "title": "Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "B Acute Lymphoblastic Leukemia", "B Lymphoblastic Lymphoma", "Central Nervous System Leukemia", "Mixed Phenotype Acute Leukemia", "Testicular Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Calaspargase Pegol", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Inotuzumab Ozogamicin", "type": "BIOLOGICAL" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG", "OTHER", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "365 Days", "maximum_age": "25 Years", "sex": "ALL", "summary": "365 Days to 25 Years" }, "enrollment_count": 5951, "start_date": "2019-10-31", "completion_date": "2032-03-31", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-27T19:31:10.828Z", "location_count": 203, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03959085" }, { "nct_id": "NCT00676143", "title": "Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "bapineuzumab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "88 Years", "sex": "ALL", "summary": "50 Years to 88 Years" }, "enrollment_count": 1100, "start_date": "2008-01", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2016-06-10", "last_synced_at": "2026-10-27T19:31:10.828Z", "location_count": 111, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 54 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00676143" }, { "nct_id": "NCT03202355", "title": "The Effect of OrthoPulse Photobiomodulation on the Rate of Tooth Movement During Alignment With Fixed Appliances", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Malocclusion" ], "interventions": [ { "name": "Fixed Appliance Orthodontic Treatment", "type": "DEVICE" }, { "name": "OrthoPulse™", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Biolux Research Holdings, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "11 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "11 Years to 60 Years" }, "enrollment_count": 10, "start_date": "2017-04-20", "completion_date": "2019-03-11", "has_results": false, "last_update_posted_date": "2019-04-08", "last_synced_at": "2026-10-27T19:31:10.828Z", "location_count": 3, "location_summary": "Chandler, Arizona • Peoria, Arizona • Phoenix, Arizona", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03202355" }, { "nct_id": "NCT01073878", "title": "Athena Pelvic Muscle Trainer - DUETS Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Urinary Incontinence" ], "interventions": [ { "name": "Athena Pelvic Muscle Trainer", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Athena Feminine Technologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "30 Years to 70 Years · Female only" }, "enrollment_count": 462, "start_date": "2010-02", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2011-07-14", "last_synced_at": "2026-10-27T19:31:10.828Z", "location_count": 96, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Casa Grande, Arizona + 87 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Casa Grande", "state": "Arizona" }, { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01073878" }, { "nct_id": "NCT03429543", "title": "Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Metformin", "type": "DRUG" }, { "name": "Insulin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Linagliptin", "type": "DRUG" }, { "name": "Empagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "10 Years to 17 Years" }, "enrollment_count": 175, "start_date": "2018-03-20", "completion_date": "2023-05-31", "has_results": true, "last_update_posted_date": "2024-02-23", "last_synced_at": "2026-10-27T19:31:10.828Z", "location_count": 44, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Orange, California + 39 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03429543" }, { "nct_id": "NCT01118052", "title": "EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Carcinoma", "Primary Peritoneal Carcinoma", "Recurrent Ovarian Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 22, "start_date": "2010-11-01", "completion_date": "2016-07-16", "has_results": true, "last_update_posted_date": "2018-01-11", "last_synced_at": "2026-10-27T19:31:10.828Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01118052" }, { "nct_id": "NCT04927247", "title": "A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sickle Cell Disease", "Vaso-occlusive Crisis", "Vaso-occlusive Pain Episode in Sickle Cell Disease" ], "interventions": [ { "name": "Inclacumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 72, "start_date": "2021-12-09", "completion_date": "2023-11-24", "has_results": true, "last_update_posted_date": "2024-12-11", "last_synced_at": "2026-10-27T19:31:10.828Z", "location_count": 17, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04927247" }, { "nct_id": "NCT00269048", "title": "SB-480848 In Subjects With Coronary Heart Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atherosclerosis" ], "interventions": [ { "name": "SB-480848", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 969, "start_date": "2005-11", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2016-08-08", "last_synced_at": "2026-10-27T19:31:10.828Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Northport, Alabama • Phoenix, Arizona + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Northport", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Spring Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00269048" }, { "nct_id": "NCT03056755", "title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Leuprolide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 383, "start_date": "2017-08-29", "completion_date": "2024-11-12", "has_results": true, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-10-27T19:31:10.828Z", "location_count": 25, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Anaheim, California + 20 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03056755" } ] }